Background: One reason for the decision to delay the introduction of an Attenuated Psychosis Syndrome in the main text of the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders was the concern that attenuated psychotic symptoms (APS) might in fact be common features in adolescents and young adults from the general population of no psychopathological significance in themselves. This concern was based on reports of high prevalence rates of psychotic-like experiences (PLEs) in the general population and the assumption that PLEs are a good estimate of APS. Although the criterion validity of self-reported PLEs had already been studied with respect to clinician-rated psychotic symptoms and found insufficient, it had been argued that PLEs might in fact be more comparable with mild, subclinical expressions of psychotic symptoms and, therefore, with APS. The present paper is the first to specifically study this assumption. Sampling and Methods: The sample consisted of 123 persons seeking help at a service for the early detection of psychosis, of whom 54 had an at-risk mental state or psychosis, 55 had a nonpsychotic mental disorder and 14 had no full-blown mental disorder. PLEs were assessed with the Peters Delusion Inventory and the revised Launay-Slade Hallucination Scale, and psychotic symptoms and APS were assessed with the Structured Interview for Prodromal Syndromes. Results: At a level of agreement between the presence of any PLE (in 98.4% of patients) and any APS (in 40.7%) just exceeding chance (κ = 0.022), the criterion validity of PLEs for APS was insufficient. Even if additional qualifiers (high agreement or distress, preoccupation and conviction) were considered, PLEs (in 52.8%) still tended to significantly overestimate APS, and agreement was only fair (κ = 0.340). Furthermore, the group effect on PLE prevalence was, at most, moderate (Cramer's V = 0.382). Conclusions: The prevalence of APS cannot be deduced from studies of PLEs. Thus, the high population prevalence rate of PLEs does not allow the conclusion that APS are common features of no pathological significance and would lack clinical validity as an Attenuated Psychosis Syndrome in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Rather, the population prevalence rate of APS has to be assumed to be largely unknown at present but is likely lower than indicated by epidemiological studies of PLEs. Therefore, dedicated studies are warranted, in which APS are assessed in a way that equates to their clinical evaluation.

Keywords:
Attenuated psychotic symptoms, Psychotic-like experiences, Self-rating, Clinician rating, Criterion validity , Attenuated psychosis syndrome
1.
Armando M, Nelson B, Yung AR, Ross M, Birchwood M, Girardi P, Fiori Nastro P: Psychotic-like experiences and correlation with distress and depressive symptoms in a community sample of adolescents and young adults. Schizophr Res 2010;119:258-265.
2.
Hanssen MS, Bijl RV, Vollebergh W, van Os J: Self-reported psychotic experiences in the general population: a valid screening tool for DSM-III-R psychotic disorders? Acta Psychiatr Scand 2003;107:369-377.
3.
Kelleher I, Cannon M: Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis. Psychol Med 2011;41:1-6.
4.
Kelleher I, Harley M, Murtagh A, Cannon M: Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull 2011;37:362-369.
5.
Kendler KS, Gallagher TJ, Abelson JM, Kessler RC: Lifetime prevalence, demographic risk factors, and diagnostic validity of non affective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 1996;53:1022-1031.
6.
Lincoln TM, Keller E, Rief W: Die Erfassung von Wahn und Halluzinationen in der Normalbevölkerung. Deutsche Adaption des Peters et al. Delusions Inventory (PDI) und der Launay Slade Hallucination Scale (LSHS-R). Diagnostica 2009;55:29-40.
7.
Stip E, Letourneau G: Psychotic symptoms as a continuum between normality and psychopathology. Can J Psychiatry 2009;54:140-151.
8.
van Os J, Hanssen M, Bijl RV, Vollebergh W: Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001;58:663-668.
9.
van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L: A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009;39:179-195.
10.
Varghese D, Scott J, Welham J, Bor W, Najman J, O'Callaghan M, Williams G, McGrath J: Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults. Schizophr Bull 2011;37:389-393.
11.
Verdoux H, Maurice-Tison S, Gay B, van Os J, Salamon R, Bourgeois ML: A survey of delusional ideation in primary-care patients. Psychol Med 1998;28:127-134.
12.
Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH: Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009;35:894-908.
13.
Woods SW, Walsh BC, Saksa JR, McGlashan TH: The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010;123:199-207.
14.
Carpenter WT: Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull 2009;35:841-843.
15.
Yung AR, Woods SW, Ruhrmann S, Addington J, Schultze-Lutter F, Cornblatt BA, Amminger GP, Bechdolf A, Birchwood M, Borgwardt S, Cannon TD, de Haan L, French P, Fusar-Poli P, Keshavan M, Klosterkötter J, Kwon JS, McGorry PD, McGuire P, Mizuno M, Morrison AP, Riecher-Rössler A, Salokangas RK, Seidman LJ, Suzuki M, Valmaggia L, van der Gaag M, Wood SJ, McGlashan TH: Whither the attenuated psychosis syndrome? Schizophr Bull 2012;38:1130-1134.
16.
Strauss JS: Hallucinations and delusions as points on continua function. Rating scale evidence. Arch Gen Psychiatry 1969;21:581-586.
17.
Chapman LJ, Chapman JP: Scales for rating psychotic and psychotic-like experiences as continua. Schizophr Bull 1980;6:476-489.
18.
Schultze-Lutter F, Schimmelmann BG, Ruhrmann S: The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull 2010;37:653-655.
19.
Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A: Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996;22:283-303.
20.
Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C: ‘A rose is a rose is a rose', but at-risk criteria differ. Psychopathology 2013;46:75-87.
21.
McGlashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L: Structured Interview for Prodromal Syndromes, version 3.0. New Haven, PRIME Research Clinic, Yale School of Medicine, 2001.
22.
Yung AR, Phillips LJ, Simmons MB, Ward J, Thompson P, French P, McGorry PD: CAARMS. Comprehensive Assessment of At Risk Mental States. Melbourne, Department of Psychiatry, University of Melbourne, 2006.
23.
Nelson B, Yung AR: Psychotic-like experiences as overdetermined phenomena: when do they increase risk for psychotic disorder? Schizophr Res 2009;108:303-304.
24.
Ochoa S, Haro JM, Torres JV, Pinto-Meza A, Palacín C, Bernal M, Brugha T, Prat B, Usall J, Alonso J, Autonell J: What is the relative importance of self reported psychotic symptoms in epidemiological studies? Results from the ESEMeD-Catalonia Study. Schizophr Res 2008;102:261-269.
25.
Werbeloff N, Drukker M, Dohrenwend BP, Levav I, Yoffe R, van Os J, Davidson M, Weiser M: Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry 2012;69:467-475.
26.
Lee YJ, Cho SJ, Cho IH, Jang JH, Kim SJ: The relationship between psychotic-like experiences and sleep disturbances in adolescents. Sleep Med 2012;3:1021-1027.
27.
Peters ER, Joseph SA, Garety PA: Measurement of delusional ideation in the normal population: introducing the PDI (Peters et al. Delusions Inventory). Schizophr Bull 1999;25:553-576.
28.
Bentall RP, Slade PD: Reliability of a scale measuring disposition towards hallucination: a brief report. Pers Individ Dif 1985;6:527-529.
29.
Stefanis NC, Hanssen M, Smirnis NK, Avramopoulos DA, Evdokimidis IK, Stefanis CN, Verdoux H, van Os J: Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 2002;32:347-358.
30.
Robins LN, Wing J, Wittchen HU, Helzer JE: The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988;45:1069-1077.
31.
Loewy RL, Johnson JK, Cannon TD: Self-report of attenuated psychotic experiences in a college population. Schizophr Res 2007;93:144-151.
32.
Yung AR, Buckby JA, Cotton SM, Cosgrave EM, Killackey EJ, Stanford C, Godfrey K, McGorry PD: Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull 2006;32:352-359.
33.
Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM: Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust NZ J Psychiatry 2009;43:118-128.
34.
Schultze-Lutter F, Ruhrmann S, Klosterkötter J: Early detection of psychosis - establishing a service for persons at risk. Eur Psychiatry 2009;24:1-10.
35.
Aleman A, Nieuwenstein MR, Böcker KBE, de Haan EHF: Temporal stability of the Launay-Slade Hallucination Scale for high- and low-scoring normal subjects. Psychol Rep 1999;85:1101-1104.
36.
Mossaheb N, Becker J, Schaefer MR, Klier CM, Schloegelhofer M, Papageorgiou K, Amminger GP: The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis. Schizophr Res 2012;141:210-214.
37.
Ising HK, Veling W, Loewy RL, Rietveld MW, Rietdijk J, Dragt S, Klaassen RM, Nieman DH, Wunderink L, Linszen DH, van der Gaag M: The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull 2012;38:1288-1296.
38.
Rietdijk J, Klaassen R, Ising H, Dragt S, Nieman DH, van de Kamp J, Cuijpers P, Linszen D, van der Gaag M: Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatr Scand 2012;126:21-30.
39.
Wilson JMG, Jungner YG: Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968.
40.
Schimmelmann BG, Michel C, Schaffner N, Schultze-Lutter F: What percentage of people in the general population satisfies the current at-risk criteria of psychosis? Schizophr Res 2010;125:99-100.
41.
Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-363.
42.
Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J: The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005;44:181-191.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.